245 related articles for article (PubMed ID: 33803356)
1. Safety and Immunogenicity of a Stable, Cold-Adapted, Temperature-Sensitive/Conditional Lethal Enterovirus A71 in Monkey Study.
Chua KB; Ng Q; Meng T; Jia Q
Viruses; 2021 Mar; 13(3):. PubMed ID: 33803356
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys.
Yang T; Xie T; Song X; Shen D; Li H; Yue L; Jiang Q; Zhu F; Meng H; Long R; Yang R; Luo F; Xie Z
Hum Vaccin Immunother; 2020 Jul; 16(7):1586-1594. PubMed ID: 32159429
[TBL] [Abstract][Full Text] [Related]
3. A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans.
Meng T; Wong SM; Chua KB
J Virol; 2021 Oct; 95(22):e0105521. PubMed ID: 34468173
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
5. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice.
Yee PTI; Tan SH; Ong KC; Tan KO; Wong KT; Hassan SS; Poh CL
Sci Rep; 2019 Mar; 9(1):4805. PubMed ID: 30886246
[TBL] [Abstract][Full Text] [Related]
6. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
7. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study.
Li Y; Zhou Y; Cheng Y; Wu P; Zhou C; Cui P; Song C; Liang L; Wang F; Qiu Q; Guo C; Zeng M; Long L; Cowling BJ; Yu H
Lancet Child Adolesc Health; 2019 Oct; 3(10):697-704. PubMed ID: 31375313
[TBL] [Abstract][Full Text] [Related]
9. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development.
Chang YK; Chen KH; Chen KT
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e70. PubMed ID: 30427405
[TBL] [Abstract][Full Text] [Related]
10. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China.
Meng XD; Tong Y; Wei ZN; Wang L; Mai JY; Wu Y; Luo ZY; Li S; Li M; Wang S; Wei S; Gong W; Zhang W; Hu X; Huang J; Shi J; Yang G; Meng S; Wang Z; Guan X; Shen S
Sci Rep; 2020 Dec; 10(1):20909. PubMed ID: 33262488
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.
Jin WP; Lu J; Zhang XY; Wu J; Wei ZN; Mai JY; Qian SS; Yu YT; Meng SL; Wang ZJ; Shen S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408178
[TBL] [Abstract][Full Text] [Related]
12. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
13. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
14. Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice.
Lee MHP; Tan CW; Tee HK; Ong KC; Sam IC; Chan YF
Vaccine; 2021 Mar; 39(12):1708-1720. PubMed ID: 33640144
[TBL] [Abstract][Full Text] [Related]
15. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Mao Q; Wang Y; Bian L; Xu M; Liang Z
Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
[TBL] [Abstract][Full Text] [Related]
16. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.
Zhao H; Li HY; Han JF; Deng YQ; Zhu SY; Li XF; Yang HQ; Li YX; Zhang Y; Qin ED; Chen R; Qin CF
Sci Rep; 2015 Jan; 5():7878. PubMed ID: 25597595
[TBL] [Abstract][Full Text] [Related]
17. microRNA-4516 Contributes to Different Functions of Epithelial Permeability Barrier by Targeting Poliovirus Receptor Related Protein 1 in Enterovirus 71 and Coxsackievirus A16 Infections.
Hu Y; Song J; Liu L; Zhang Y; Wang L; Li Q
Front Cell Infect Microbiol; 2018; 8():110. PubMed ID: 29686973
[TBL] [Abstract][Full Text] [Related]
18. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
19. Immune responses of a CV-A16 live attenuated candidate strain and its protective effects in rhesus monkeys.
Yang T; Xie T; Li H; Song X; Yue L; Wang X; Shen D; Ma K; Jiang Q; Long R; Yang R; He X; Zhang Y; Xie Z; Li Q
Emerg Microbes Infect; 2020 Dec; 9(1):2136-2146. PubMed ID: 32930072
[TBL] [Abstract][Full Text] [Related]
20. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
